EU-PEARL aims to improve health outcomes for patients by transforming the way clinical trials are conducted. To achieve this highly ambitious goal, the public and private sector have formed this strategic alliance which will lay the foundations for the future of medicines development in the EU. The generic framework and additional instruments EU-PEARL is developing to conduct collaborative platform trials, will help improve and accelerate medicine development processes, thus increasing access to new and more effective treatments, faster.   Visit our website for more information. EU-PEARL has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853966-2. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. Any related posts reflect only the views of the author.